The Department of Defense removed newly posted guidelines regarding mandatory testosterone deficiency screenings for male service members aged 30 and older from its website shortly after their release earlier this week, a U.S. official confirmed.
The directives originated from a mid-July announcement by Defense Secretary Pete Hegseth, which mandated that active-duty and reserve male personnel in that age group undergo testosterone testing as part of annual health check-ups. Hegseth noted that while clinicians would recommend testosterone replacement therapy if deficiencies were found, the decision to pursue treatment would rest with the individual service member.
The proposal faced immediate scrutiny from medical experts, who questioned the clinical necessity of such widespread screening and treatment protocols.
On Wednesday, Pentagon spokesman Sean Parnell issued a press release stating that the Director of the Defense Health Agency (DHA) had provided comprehensive clinical guidance to establish uniform screening and treatment pathways across the military medical system. The release referenced three documents containing specific medical guidance hosted on the DHA website.
However, by Thursday, those documents had been taken down. A U.S. official stated that the “Clinical Guidance for Health and Human Performance Optimization,” published on September 2, 2026, was temporarily rescinded to allow for updates.
“The ‘Interim Guidance on Testosterone Deficiency Screenings for Active Duty and Reserve Component Personnel’ remains in effect. The final clinical guidance will be issued shortly,” the official said.
While the removed guidelines included specific testing protocols for men, they also advised that female service members be questioned about fatigue and disrupted menstrual cycles potentially linked to hormonal dysregulation.
No official reason was initially provided for the removal, but on Friday, Tim Parlatore, a senior advisor to Hegseth, characterized the posted documents as a “draft” that had been published “inadvertently.”
“What was posted earlier this week was something that was a draft. It was not approved for release,” Parlatore told CNN. “Somebody had put it out there inadvertently. And so, we needed to pull that back because we need a lot more input to make sure that the information on that reflected the current science and medical science and medical guidance, as opposed to certain antiquated protocols.”
It remains unclear when the updated DHA clinical guidance will be released.
Low testosterone has long been a concern within the military, particularly among special operations forces where high stress, intense physical labor, and caloric deficits may negatively impact hormone levels, though research in this area is ongoing. While Testosterone Deficiency is a rare medical condition, some physicians warn that the growing online discourse around “low-T” may create a mistaken perception that the issue is more widespread than medical data supports.
Calling it a ‘draft’ explains the scramble, but medical experts should be consulted before rolling out mandatory hormone screenings for troops.
Did they pull it because it was unapproved, or because specialists pushed back on the science? Either way, clarity matters.